FDA Clears New Implant to Revolutionize Big Toe Arthritis Treatment

LEXINGTON, MA – April 21, 2026 – Hyalex Orthopaedics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HYALEX Slalom™ MTP Hemiarthroplasty System. The clearance marks the commercial debut for the Lexington-based company and introduces a novel, motion-preserving treatment for patients suffering from hallux rigidus, a common and debilitating form of arthritis in the big toe joint.

The Slalom™ implant is built around the company’s proprietary Hydrosurf™ materials platform, a synthetic cartilage technology designed to replicate the low-friction, durable properties of natural joint surfaces. This approval positions Hyalex to enter the competitive foot and ankle reconstruction market with a solution that directly challenges the long-standing surgical standard of care, joint fusion.

“The FDA clearance of the HYALEX Slalom™ MTP Implant is a pivotal milestone that validates our technology and accelerates our transition into a commercial-stage company,” said Carl Vause, Chief Executive Officer of Hyalex Orthopaedics, in a company statement. “We believe this system addresses a significant unmet clinical need while opening a meaningful market opportunity for tissue and motion-preserving solutions in first MTP joint disease.”

A New Player in a Growing Market

Hyalex enters a substantial and expanding market. The global hallux rigidus treatment market was valued at an estimated $2.8 billion in 2025 and is projected to grow at a compound annual rate of 6.4%, driven by an aging population and an increasing prevalence of the condition, which affects roughly one in 40 adults over the age of 50. The U.S. market, where Hyalex will initially launch, is particularly robust, accounting for the largest regional share of global revenue.

The orthopedic extremities market is currently dominated by established giants like Arthrex, Stryker, and Zimmer Biomet. These companies have historically focused on arthrodesis, or fusion, systems—the gold standard for severe hallux rigidus. Hyalex’s strategy is not to compete head-on with existing fusion products but to offer a disruptive alternative that aligns with a growing preference for preserving natural function.

With this clearance, Hyalex is initiating a limited U.S. market release, focusing on targeted surgeon training programs and building a strategic sales channel. A full commercial rollout is planned for later this year, a move the company believes will allow it to capture a significant share of what it terms a sizable and underpenetrated segment of the market.

Beyond Fusion: The Clinical Challenge of Hallux Rigidus

For decades, patients with end-stage hallux rigidus faced a difficult choice. The condition causes pain, stiffness, and a loss of mobility that can severely impact a person's ability to walk, run, or even wear certain shoes. The most reliable surgical solution has been arthrodesis, a procedure that fuses the bones of the first metatarsophalangeal (MTP) joint, creating a rigid, immovable toe.

While fusion is highly effective at eliminating pain—with patient satisfaction rates often exceeding 80%—it comes at the cost of motion. This permanent loss of movement can alter a person's gait, limit their ability to participate in high-impact sports, and restrict footwear choices. As one orthopedic surgeon specializing in foot and ankle procedures noted, “Patients often want to return to an active lifestyle, and while fusion provides pain relief, the inability to bend the toe is a significant compromise for many.”

This trade-off has fueled a search for viable, motion-preserving alternatives. Hemiarthroplasty, which involves replacing only one side of the joint, has emerged as a promising option. Modern implants aim to provide the pain relief of fusion while maintaining the natural kinematics of the foot. The HYALEX Slalom™ system is the latest and arguably one of the most advanced entries into this category.

“From a clinical standpoint, restoration of motion in the first MTP joint remains a primary objective in treating hallux rigidus,” stated Nicholas Strasser, MD, of Vanderbilt University Medical Center. “A hemiarthroplasty solution that delivers consistent, functional range of motion represents a meaningful advancement over traditional fusion.”

The Science of Motion: Inside Hydrosurf™ Technology

The key differentiator for the Slalom™ implant is the Hydrosurf™ material. Developed from technology licensed from Stanford University, Hydrosurf™ is a synthetic polymer designed to mimic the structure and function of hyaline cartilage, the smooth, resilient tissue that lines healthy joints. It features a unique dual-polymer structure: a hydrophobic side that adheres firmly to bone cement and a hydrophilic, water-loving side that creates a lubricious, low-friction surface for articulation.

This biomimetic design allows the material to manage joint-loading forces through fluid flow, much like natural cartilage, providing a durable, low-wear bearing surface. The company’s HYALEX Cartilage System, which uses the same core technology, previously received a Breakthrough Device Designation from the FDA for use in the knee, underscoring the platform's innovative potential. Pre-clinical studies have demonstrated the material's durability and its ability to protect opposing cartilage surfaces from damage.

The Slalom™ MTP implant combines this advanced material with an anatomically contoured implant geometry, engineered to restore natural joint kinematics. It is supported by a streamlined set of surgical instruments designed to make the procedure efficient and reproducible for surgeons.

From Lab to Launch: Hyalex's Strategic Ascent

Founded in 2016, Hyalex Orthopaedics has been on a steady trajectory, transforming from a research-focused startup into a commercial-stage medical device company. Its progress has been backed by significant investment, having raised over $46 million from venture capital firms including Canaan Partners, Osage University Partners, and Johnson & Johnson Innovation – JJDC Inc.

The company has also assembled a veteran leadership team with deep experience in the orthopedic industry. CEO Carl Vause previously held leadership roles at CONMED, Soft Robotics Inc., and Smith & Nephew, while the technical and medical leadership includes seasoned experts from Zimmer Holdings and UCSF. This combination of strong financial backing and industry expertise has enabled Hyalex to navigate the complex regulatory pathway and bring its first product to market.

The Slalom™ MTP system is just the first step. The company is also advancing its HYALEX Freestyle™ Knee Resurfacing System, which is currently approved for a clinical trial in the United States. This broader pipeline demonstrates a clear strategy to leverage the Hydrosurf™ platform across multiple joints, addressing a wide range of degenerative conditions. With its first commercial product now cleared, Hyalex is poised to make its mark on the orthopedic landscape, offering patients an opportunity to maintain their motion and their lifestyle.